IRWD
Ironwood Pharmaceuticals, Inc.
$10.59
Earnings Summary
Revenue | $94.21Mn |
Net Profits | $12.09Mn |
Net Profit Margins | 12.83% |
Highlights
Ironwood Pharmaceuticals, Inc.’s revenue jumped 7.72% since last year same period to $94.21Mn in the Q4 2017. On a quarterly growth basis, Ironwood Pharmaceuticals, Inc. has generated 8.5% jump in its revenue since last 3-months.
Ironwood Pharmaceuticals, Inc.’s net profit jumped 189.49% since last year same period to $12.09Mn in the Q4 2017. On a quarterly growth basis, Ironwood Pharmaceuticals, Inc. has generated 137.42% jump in its net profits since last 3-months.
Ironwood Pharmaceuticals, Inc.’s net profit margin jumped 183.07% since last year same period to 12.83% in the Q4 2017. On a quarterly growth basis, Ironwood Pharmaceuticals, Inc. has generated 134.49% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Ironwood Pharmaceuticals, Inc. post its latest quarter earnings
EPS Estimate Current Quarter | 0.3 |
EPS Estimate Current Year | 0.3 |
Highlights
Ironwood Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.3 - a 11.11% jump from last quarter’s estimates.
Ironwood Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at 0.3.
Key Ratios
Key ratios of the Ironwood Pharmaceuticals, Inc. post its Q4 2022 earnings
Return on Assets (ROA) | 0.14 |
Return on Equity (ROE) | 0.28 |
Highlights
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ironwood Pharmaceuticals, Inc.’s return on assets (ROA) stands at 0.14.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ironwood Pharmaceuticals, Inc.’s return on equity (ROE) stands at 0.28.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2020-02-13 | 0.24 | 0.3 | 25% |
2019-10-31 | 0.11 | 0.4 | 263.64% |
2019-07-30 | -0.03 | 0.1 | 433.33% |
2019-05-02 | -0.14 | -0.26 | -85.71% |
Company Information
Ironwood Pharmaceuticals is a GI-focused healthcare company dedicated to creating medicines that make a difference for patients living with GI diseases. The company discovered, developed and are commercializing linaclotide, the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Organisation | Ironwood Pharmaceuticals, Inc. |
Headquarters | 100 Summer Street, Boston, MA, United States, 02110 |
Employees | 219 |
Industry | Health Technology |
CEO | Mark Mallon |
